Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Sarno

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Epigenetics|December 3, 2019
DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatmentFederica Sarno, Angela Nebbioso, Lucia Altucci
Epigenetics|October 22, 2016
Identification and characterization of PKF118-310 as a KDM4A inhibitorGianluigi Franci, Federica Sarno, Angela Nebbioso, et al.
Advances in Experimental Medicine and Biology|November 9, 2022
Gene-Targeted DNA Methylation: Towards Long-Lasting Reprogramming of Gene Expression?Fabian M Cortés-Mancera, Federica Sarno, Désirée Goubert, et al.
Pharmaceutics|March 28, 2024
Cancer Therapy Resistance: Choosing Kinase InhibitorsCarmela Dell'Aversana, Federica Sarno, Rosaria Benedetti, et al.
Sub-Cellular Biochemistry|January 17, 2025
The Promise of Epigenetic Editing for Treating Brain DisordersLuis A González Molina, Amalia M Dolga, Marianne G Rots, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2024
Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic EditingFederica Sarno, Mihaly Koncz, Roos E Eilers, et al.
Clinical Epigenetics|June 19, 2025
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approachFederica Sarno, Jim J Jacob, Roos E Eilers, et al.
Frontiers in Pharmacology|September 25, 2018
3-Chloro-<i>N</i>'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer TherapyFederica Sarno, Chiara Papulino, Gianluigi Franci, et al.
Cells|February 12, 2020
<i>Trifolium Repens</i> Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 PathwayFederica Sarno, Giacomo Pepe, Pasquale Termolino, et al.
Expert Opinion on Therapeutic Patents|December 10, 2025
Lysine demethylase (KDM) inhibitors for the treatment of cancer: a patent review (2015-present)Federica Sarno, Mariarosaria Conte, Annamaria Muro, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Epigenetics|December 3, 2019
DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatmentFederica Sarno, Angela Nebbioso, Lucia Altucci
Epigenetics|October 22, 2016
Identification and characterization of PKF118-310 as a KDM4A inhibitorGianluigi Franci, Federica Sarno, Angela Nebbioso, et al.
Advances in Experimental Medicine and Biology|November 9, 2022
Gene-Targeted DNA Methylation: Towards Long-Lasting Reprogramming of Gene Expression?Fabian M Cortés-Mancera, Federica Sarno, Désirée Goubert, et al.
Pharmaceutics|March 28, 2024
Cancer Therapy Resistance: Choosing Kinase InhibitorsCarmela Dell'Aversana, Federica Sarno, Rosaria Benedetti, et al.
Sub-Cellular Biochemistry|January 17, 2025
The Promise of Epigenetic Editing for Treating Brain DisordersLuis A González Molina, Amalia M Dolga, Marianne G Rots, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 16, 2024
Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic EditingFederica Sarno, Mihaly Koncz, Roos E Eilers, et al.
Clinical Epigenetics|June 19, 2025
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approachFederica Sarno, Jim J Jacob, Roos E Eilers, et al.
Frontiers in Pharmacology|September 25, 2018
3-Chloro-<i>N</i>'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer TherapyFederica Sarno, Chiara Papulino, Gianluigi Franci, et al.
Cells|February 12, 2020
<i>Trifolium Repens</i> Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 PathwayFederica Sarno, Giacomo Pepe, Pasquale Termolino, et al.
Expert Opinion on Therapeutic Patents|December 10, 2025
Lysine demethylase (KDM) inhibitors for the treatment of cancer: a patent review (2015-present)Federica Sarno, Mariarosaria Conte, Annamaria Muro, et al.
Pageof 4